Parkinson's Disease Market Size in the 7MM was approximately USD 3,300 Million in 2022, estimates DelveInsight

"The Parkinson's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Parkinson's Disease pipeline products will significantly revolutionize the Parkinson's Disease market dynamics"

The Parkinson's Disease market report provides current treatment practices, Parkinson's Disease emerging drugs, market share of individual therapies, and current and forecasted 7MM Parkinson's Disease market size from 2019 to 2032. The report also covers current Parkinson's Disease treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Key Takeaways from the Parkinson's Disease Market Research Report
• The Parkinson's disease market size in the 7MM will increase at a CAGR of 11.2% due to the increase in diagnosed prevalent cases of the disease and the anticipated launch of emerging Parkinson's disease therapies.
• The leading companies working in the Parkinson's Disease Market include Newron Pharmaceuticals, Kyowa Kirin, AbbVie, Acadia Pharmaceuticals, Inc., Acorda Therapeutics Inc, Hisamitsu Pharmaceutical Co. Inc., Sunovion Pharmaceuticals, Adamas Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Pharma Two B, Mitsubishi Tanabe Pharma, Amneal Pharmaceuticals, Addex Pharma S.A., Ipsen, Annovis Bio Inc., and others.
• Promising Parkinson's Disease Pipeline Therapies in the various stages of development include BIIB122, LY03003 ( Rotigotine, extended-release microspheres), Istradefylline 20 mg or 40 mg, and others.
• September 2023: Prevail Therapeutics announced a study of phase 1 & 2 clinical trials for LY3884961, Methylprednisolone, and Sirolimus. Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years.
• September 2023: FAScinate Therapeutics Inc. announced a study of phase 2 clinical trials for KM-819. The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson's disease. The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson's disease.

Discover more about therapies set to grab major Parkinson's Disease Market Share @ Parkinson's Disease Market Size- https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Overview
Parkinson's disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. The cause of Parkinson's disease remains unknown but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility. The majority of cases are thought to arise sporadically, although up to 20% of people with Parkinson's disease also have a first-degree relative with Parkinson's disease.

Parkinson's Disease Epidemiology Segmentation in the 7MM
• Parkinson's Disease Diagnosed Prevalent Population
• Parkinson's Disease Gender-specific Diagnosed Prevalent Population
• Parkinson's Disease Age-specific Diagnosed Prevalent Population
• Parkinson's Disease Stage-specific Diagnosed Prevalent Population

Download the report to understand which factors are driving Parkinson's Disease Epidemiology Trends @ Parkinson's Disease Epidemiological Insights- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's disease Emerging Drugs
• Tavapadon: Cerevel Therapeutics/Pfizer

Parkinson's Disease Market Outlook
Accurate diagnosis, and pharmacologic treatments are all important aspects of managing Parkinson's disease. There are different types of medications available in Parkinson's disease market. Available medicines cannot reverse Parkinson's disease; however, they are used to manage symptoms that affect movement in people with Parkinson's disease. DelveInsight's market forecast focus on the market revenue generated by pharmacological therapies (including all the currently used therapies) prescribed for the management of Parkinson's disease and doesn't comprise the revenue generated by devices &/or surgical procedures.

To learn more about Parkinson's Disease Treatment options, visit @ Parkinson's Disease Drugs- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Drugs Market
For the purpose of study, the Parkinson's disease drugs market is categorized on the basis of medications treat Parkinson's disease including, levodopa dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists.

Parkinson's Disease Market Access and Reimbursement
According to Yang et al. (2020), there were approximately 1 million individuals diagnosed with Parkinson's disease in 2017, and a total economic burden of USD 51.9 billion. The total burden of Parkinson's disease includes direct medical costs of USD 25.4 billion and USD 26.5 billion in indirect and nonmedical costs, including an indirect cost of USD 14.2 billion (persons with Parkinson's disease [PWP] and caregiver burden combined), nonmedical costs of USD 7.5 billion, and USD 4.8 billion due to disability income received by PWPs. The Medicare program bears the largest share of excess medical costs, as most Parkinson's disease patients are over age 65. The projected prevalence will be more than 1.6 million with a projected total economic burden surpassing USD 79 billion by 2037. The costs of informal caregivers comprise an important subgroup of the total costs and are often greater than direct costs. Furthermore, since most patients require informal care, these costs pose a significant burden.

Learn more about the Parkinson's Disease Pipeline Therapies in clinical trials @ Parkinson's Disease Market Landscape- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Parkinson's Disease Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Parkinson's Disease Companies- Newron Pharmaceuticals, Kyowa Kirin, AbbVie, Acadia Pharmaceuticals, Inc., Acorda Therapeutics Inc, Hisamitsu Pharmaceutical Co. Inc., Sunovion Pharmaceuticals, Adamas Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Pharma Two B, Mitsubishi Tanabe Pharma, Amneal Pharmaceuticals, Addex Pharma S.A., Ipsen, Annovis Bio Inc., and others.
• Parkinson's Disease Pipeline Therapies- BIIB122, LY03003 ( Rotigotine, extended-release microspheres), Istradefylline 20 mg or 40 mg, and others.
• Parkinson's Disease Market Dynamics: Parkinson's Disease Market Drivers and Barriers
• Parkinson's Disease Market Access and Reimbursement, Unmet Needs, and Future Perspectives

Discover more about Parkinson's Disease Drugs in development @ Parkinson's Disease Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Parkinson's disease Market Overview at a Glance
4. Executive Summary of Parkinson's disease
5. Key Events
6. Parkinson's disease Epidemiology and Market Methodology
7. Parkinson's disease Background and Overview
8. Parkinson's disease Epidemiology and Patient Population
9. Parkinson's disease Patient Journey
10. Parkinson's disease Marketed Products
11. Emerging Parkinson's disease Therapies
12. Parkinson's disease: The 7MM Analysis
13. Parkinson's disease KOL Views
14. Parkinson's disease SWOT Analysis
15. Parkinson's disease Unmet Needs
16. Parkinson's disease Market Access and Reimbursement
17. Acronyms and Abbreviations
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Important Published Links

https://logcworld.mn.co/posts/46134506
https://marketingops.mn.co/posts/46134636
https://motorcycle-events.mn.co/posts/46134899
https://intuitive-schooling.mn.co/posts/46135011
https://plenty-of-heathens.mn.co/posts/advancements-and-market-trends-in-langerhans-cell-histiocytosis-treatment
https://shopsanity.mn.co/posts/understanding-the-langerhans-cell-histiocytosis-market-current-landscape-and-future-prospects
https://mccoterie.mn.co/posts/46135751
https://go02100.mn.co/posts/46136119
https://freesaloneducation.mn.co/posts/46136215
https://sokomtaani.mn.co/posts/46136615
https://skillcrush.mn.co/posts/46136691
https://advicehonest.mn.co/posts/46136795
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/45816438
https://council-of-light.mn.co/posts/45816468
https://chanspirations.mn.co/posts/45816726
https://hulu-com-forgot.mn.co/posts/45816832
https://bucketseems-news.mn.co/members/20271966
https://sentinels.mn.co/members/20272156
https://akademe.mn.co/posts/navigating-the-acne-vulgaris-market-trends-treatments-and-technological-advances
https://tc-2345.mn.co/posts/45818004
https://gene-keys-genealogy.mn.co/posts/45818150
https://take-your-phone.mn.co/posts/45818381
https://digitaldrip.mn.co/posts/45818561
https://network-24921.mn.co/posts/45818644
https://friends-of-zizira.mn.co/members/20272206
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

This release was published on openPR.